• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
TLX 1.65% $18.44


Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The... Telix Pharmaceuticals Limited is an Australia-based biopharmaceutical company. The Company is focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. It is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Its core pipeline is focused on prostate cancer, renal cancer, brain cancer (glioma) and rare diseases (hematologic cancers and bone marrow conditioning). Its pipelines include TLX591, TLX592 (alpha-RADmAb), TLX591-CDx, TLX250, TLX250-CDx, TLX101, TLX101-CDx, TLX300, TLX300-CDx, TLX66, and TLX66-CDx. TLX591 is a radio antibody-drug conjugate (rADC) directed at prostate-specific membrane antigen (PSMA). Its product QUANTM Irradiation System (QIS), enables production of important medical isotopes such as gallium-68 (68Ga), zirconium-89 (89Zr), technetium-99m (99mTc) and copper-64 (64Cu).More

refresh Created with Sketch. REFRESH
Last update - 15.59pm 21/06/2024 (20 minute delay) ?
Open $18.25   Day High $18.46   Day Low $17.91
Daily Volume 2328765
Bids   Sellers
Number Price Volume   Number Price Volume
1 $18.41 5117   6 $18.44 42145

Directors & Senior Management

Dr. Christian P. Behrenbruch Group Chief Executive Officer, Managing Director, Executive Director
Mr. Darren Smith Group Chief Financial Officer
Mr. Raphael Ortiz Chief Executive Officer - APAC and EMEA
Mr. Kevin Richardson Chief Executive Officer, Americas
Dr. Darren Patti Group Chief Operating Officer
Ms. Lena Moran - Adams Group General Counsel
Dr. David Cade Group Chief Medical Officer
Mr. James Stonecypher Group Chief Development Officer
Mr. Richard Valeix Group Chief Commercial Officer
Ms. Genevieve Ryan Company Secretary
Mr. H. Kevin Mccann Non-Executive Independent Chairman of the Board
Dr. Andreas Kluge Non-Executive Director
Dr. Mark Nelson Non-Executive Independent Director
Ms. Tiffany P. Olson Non-Executive Independent Director
Ms. Jann Skinner Non-Executive Independent Director

Data source: Refinitiv

(20min delay)
Mkt cap ! $6.161B
Open High Low Value Volume
$18.25 $18.46 $17.91 $42.70M 2.328M

Buyers (Bids)

No. Vol. Price($)
1 5117 $18.41

Sellers (Offers)

Price($) Vol. No.
$18.44 42145 6
View Market Depth
Last trade - 16.10pm 21/06/2024 (20 minute delay) ?
0.300 ( 1.96 %)
Open High Low Volume
$18.23 $18.46 $17.93 237725
Last updated 15.59pm 21/06/2024 ?
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.